Stocks
ArriVent BioPharma, Inc.AVBP
NASDAQHealthcareBiotechnology$21.00
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted therapies for cancer, with a focus on precision oncology. Its lead programs aim to address specific genetic mutations, positioning it as a potential player in the emerging targeted therapy market. Investors track the company for its pipeline progress and clinical trial outcomes.
52W Range: $11.36-$35.83
Congressional Interest in ArriVent BioPharma, Inc. (AVBP)
No congressional trades have been disclosed for ArriVent BioPharma, Inc. (AVBP) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading AVBP?
No congressional trades found for this stock.